732
Views
19
CrossRef citations to date
0
Altmetric
Reviews

Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia

, &
Pages 851-863 | Published online: 22 Jan 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sigal Kaplan, Nicole Lang, Maja Gasparic, Carolyn Rainville, George Haralabopoulos & Emanuele Borroni. (2019) Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe. Journal of Drug Assessment 8:1, pages 70-76.
Read now
Marco Danova, Sandro Barni, Lucia Del Mastro, Romano Danesi & Giovanni L Pappagallo. (2011) Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. Expert Review of Anticancer Therapy 11:8, pages 1303-1313.
Read now

Articles from other publishers (17)

Yu Xu, Yan Li, Yiwei Fu, Bo Wang, Tiao Lin, Changye Zou, Gang Huang, Jingnan Shen & Junqiang Yin. (2023) Autologous menisci–cruciate ligament composite as a flap for soft tissue reconstruction following malignant bone tumor resection around the knee. Cancer Medicine 12:7, pages 8027-8037.
Crossref
Maria Aquino, Maria Tinoco, Joana Bicker, Amílcar Falcão, Marília Rocha & Ana Fortuna. (2023) Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients. Antibiotics 12:2, pages 373.
Crossref
Sigal Kaplan, Dana Ilic Bogojevic, Carolyn Rainville & Nicholas Gross. (2022) A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe. Supportive Care in Cancer 30:11, pages 9191-9201.
Crossref
Minjeong Nam, Sumi Yoon, Mina Hur, Gun Hyuk Lee, Hanah Kim, Mikyoung Park & Hyeong Nyeon Kim. (2022) Digital Morphology Analyzer Sysmex DI-60 vs. Manual Counting for White Blood Cell Differentials in Leukopenic Samples: A Comparative Assessment of Risk and Turnaround Time. Annals of Laboratory Medicine 42:4, pages 398-405.
Crossref
Gina Wong, Katie Wang, Mark Pasetka, Liying Zhang, Julia Lou, Habeeb Majeed, Jerome Flores, Emily Lam & Carlo DeAngelis. (2022) The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study. Current Oncology 29:3, pages 1349-1369.
Crossref
Gina Wong, Liying Zhang, Habeeb Majeed, Yasmeen Razvi, Carlo DeAngelis, Emily Lam, Erin McKenzie, Katie Wang & Mark Pasetka. (2020) A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®). Journal of Oncology Pharmacy Practice 28:1, pages 5-16.
Crossref
Patricia Diaz, Bo-Young Hong, Amanda Dupuy, Linda Choquette, Angela Thompson, Andrew Salner, Peter Schauer, Upendra Hegde, Joseph Burleson, Linda Strausbaugh, Douglas Peterson & Anna Dongari-Bagtzoglou. (2019) Integrated Analysis of Clinical and Microbiome Risk Factors Associated with the Development of Oral Candidiasis during Cancer Chemotherapy. Journal of Fungi 5:2, pages 49.
Crossref
Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes & Steven Simoens. (2017) Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Frontiers in Pharmacology 8.
Crossref
Samuel J. Taylor, Johanna M. DuyvestynSamantha A. Dagger, Emma J. DishingtonCatherine A. RinaldiOliver M. Dovey, George S. Vassiliou, Carolyn S. Grove & Wallace Y. Langdon. (2017) Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. Science Translational Medicine 9:402.
Crossref
S. Cancedda, C. Rohrer Bley, L. Aresu, M. Dacasto, V. F. Leone, S. Pizzoni, M. Gracis & L. Marconato. (2016) Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma. Veterinary and Comparative Oncology 14:4, pages e146-e157.
Crossref
JAVIER DE CASTRO CARPEÑO, PERE GASCÓN-VILAPLANA, ANA MARIA CASAS-FERNÁNDEZ-DE TEJERINA, ANTONIO ANTÓN-TORRES, RAFAEL LÓPEZ-LÓPEZ, AGUSTÍ BARNADAS-MOLINS, JUAN JESÚS CRUZ-HERNÁNDEZ, BARTOMEU MASSUTI-SUREDA, CARLOS CAMPS-HERRERO, ENRIQUE ARANDA-AGUILAR & FRANCISCO JOSÉ REBOLLO LASERNA. (2015) Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Molecular and Clinical Oncology 3:3, pages 725-729.
Crossref
Alena M. Pfeil, Kim Allcott, Ruth Pettengell, Gunter von Minckwitz, Matthias Schwenkglenks & Zsolt Szabo. (2014) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Supportive Care in Cancer 23:2, pages 525-545.
Crossref
Jimin Kahng, Yonggoo Kim, Myungshin Kim, Eun-Jee Oh, Yeon-Joon Park & Kyungja Han. (2015) Flow Cytometric White Blood Cell Differential Using CytoDiff is Excellent for Counting Blasts. Annals of Laboratory Medicine 35:1, pages 28-34.
Crossref
Christopher Heylman, Agua Sobrino, Venktesh S Shirure, Christopher CW Hughes & Steven C George. (2014) A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. Experimental Biology and Medicine 239:9, pages 1240-1254.
Crossref
Ah Hyun KimWonbae LeeMyungshin KimYonggoo KimKyungja Han. (2014) White blood cell differential counts in severely leukopenic samples: a comparative analysis of different solutions available in modern laboratory hematology. Blood Research 49:2, pages 120.
Crossref
Cheng-Suo Huang, Lin Liu, Jie Liu, Zhen Chen, Jun Guo, Chang-Zheng Li, Deng-Guang Zhou & Zhe-Hai Wang. (2012) Association of Chemotherapy-induced Leucopenia with Treatment Outcomes in Advanced Non-small-cell lung Cancer Cases Receiving the NP Regimen. Asian Pacific Journal of Cancer Prevention 13:9, pages 4481-4485.
Crossref
K Haerian, D Varn, S Vaidya, L Ena, H S Chase & C Friedman. (2012) Detection of Pharmacovigilance-Related Adverse Events Using Electronic Health Records and Automated Methods. Clinical Pharmacology & Therapeutics 92:2, pages 228-234.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.